Scott + Scott, LLP Announces Investigation of Zosano Pharma Corp (ZSAN), Encourages Investors with Losses to Contact Firm

NEW YORK, Sept. 29, 2016 -- Scott + Scott, Attorneys at Law, LLP, a global shareholder rights litigation firm, has opened an investigation on behalf of investors in Zosano Pharma Corp (ZSAN). The investigation focuses on whether Zosano and certain of its executives and directors made false statements to investors about the Company’s osteoporosis drug program, ZP-PTH, and its collaboration agreement with Eli Lily and Company.

Investors who own Zosano stock are encouraged to contact Scott + Scott at (646)-582-0121 or email [email protected] to discuss their legal rights.

About the Investigation

Scott + Scott, LLP is investigating potential violations of the federal securities laws in connection with the Company’s January 27, 2015 Initial Public Offering (“IPO”). In particular, the firm is investigating whether Zosano and certain of its executives and directors made false statements and omitted material information about the Company’s osteoporosis drug program, ZP-PTH, and its collaboration agreement with Eli Lily and Company.

What You Can Do

If you purchased shares of Zosano, you may have legal claims against the Company. If you wish to discuss the investigation, or have questions about your legal rights, please contact Joseph Halloran, Esq. by telephone at (646)-582-0121 or by email at [email protected].

About Scott + Scott, Attorneys at Law, LLP

Scott + Scott, Attorneys at Law, LLP has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California and Ohio. Please visit www.scott-scott.com for more information about the firm.

Contact

Scott + Scott, Attorneys at Law, LLP
Joseph Halloran
646.582.0121 
[email protected]